Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 17/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13608405 | 0.87 | USP1 (0.43) | USP1ADORA3 | |
| SCHEMBL13620075 | 0.87 | BRD4 (0.43) | USP1ADORA3JAK2JAK3 | |
| SCHEMBL13620401 | 0.84 | TLR7 (0.39) | USP1ADORA3TLR7JAK2JAK3 | |
| SCHEMBL13620291 | 0.82 | USP1 (0.41) | USP1ADORA3TLR7 | |
| SCHEMBL12371744 | 0.77 | JAK2 (0.42) | USP1ADORA3JAK2JAK3 | |
| SCHEMBL12371717 | 0.75 | ALDH1A1 (0.41) | USP1ADORA3TLR7JAK2JAK3 | |
| SCHEMBL12371741 | 0.74 | ADORA2A (0.44) | USP1ADORA3 | |
| SCHEMBL13620235 | 0.74 | HSP90AA1 (0.41) | TLR7JAK2JAK3 | |
| SCHEMBL12371672 | 0.73 | ADORA2A (0.43) | ADORA3TLR7JAK2JAK3 | |
| SCHEMBL12371796 | 0.73 | JAK2 (0.42) | USP1ADORA3JAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PHARMACOPEIA, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281075-A1 | ISOMERIC PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS | PRKCE, PRKCZ, PRKCQ | USP1 3253/4885ADORA3 1135/4885TLR7 3960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.